Table 1. Patient characteristics.
| Characteristics | Cohort 1 | Cohort 2 | Cohort 3 | |
|---|---|---|---|---|
| Non-sorafenib (n = 297) |
Sorafenib (n = 69) |
Non-sorafenib (n = 74) |
Sorafenib (n = 83) |
|
| Age (years, median [range]) | 52 (22−80) | 55 (28−75) | 55 (32−76) | 52 (18−75) |
| Gender (male/female) | 248/49 | 61/8 | 62/12 | 77/6 |
| Hepatitis B history (yes/no) | 255/42 | 58/11 | 56/18 | 69/14 |
| Hepatitis B e antigen (positive/negative) | 113/184 | 22/47 | 14/60 | 22/61 |
| Preoperative ALT (U/L, median [range]) | 42 (9−208) | 44 (5−184) | 51 (8−272) | 35 (2−187) |
| α-Fetoprotein (ng/dl, median [range]) | 164 (0−60500) | 248 (0−60500) | 256 (0−60500) | 196 (0−60500) |
| Liver cirrhosis (yes/no) | 228/69 | 61/8 | 60/14 | 64/19 |
| Tumor size (cm, mean ± SD) | 5.57 ± 3.93 | 5.32 ± 4.41 | 5.37 ± 3.88 | 6.73 ± 4.91 |
| Tumor differentiation (high/low) | 209/88 | 26/43 | 41/33 | NE |
| Tumor number (multiple/single) | 39/258 | 20/49 | 11/63 | 68/15 |
| Intrahepatic metastasis (yes/no) | 43/254 | 34/35 | 32/42 | NE |
| Tumor encapsulation (complete/no) | 145/152 | 28/41 | 22/52 | NE |
| Microvascular invasion (yes/no) | 119/178 | 30/39 | 24/50 | 49/34 |
| UICC TNM stage (I/II/IIIA) | 36/128/133 | 10/39/20 | 8/25/41 | NE |
Abbreviations: ALT, alanine aminotransferase; SD, standard deviation; NE, not evaluated; UICC, International Union Against Cancer Classification; TNM, tumor-node-metastasis.